PPLPHARMA.NSPPLPHARMA.NSNSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +12.54% | +7.90% | -0.89% | -8.83% | -2.92% |
| Gross Profit Growth | +8.96% | +291.07% | +141.87% | -24.02% | -61.31% |
| EBITDA Growth | +23.29% | -4.51% | -8.76% | -44.31% | -46.08% |
| Operating Income Growth | +71.76% | +889.16% | -554.26% | -129.55% | -112.07% |
| Net Income Growth | -63.60% | +51.57% | +0.00% | -539.22% | -3800.82% |
| EPS Growth | -62.50% | +50.65% | +0.00% | -541.18% | -3533.33% |
| EPS Diluted Growth | -62.50% | +50.65% | +0.00% | -541.18% | -3533.33% |
| Weighted Average Shares Growth | -2.93% | +3.96% | -0.40% | -0.59% | +7.71% |
| Weighted Average Shares Diluted Growth | -2.93% | +3.96% | -0.40% | -0.59% | +7.71% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +9.24% | +0.00% | +8.62% | +0.00% |
| Inventory Growth | +0.00% | +6.29% | +0.00% | +12.07% | +0.00% |
| Asset Growth | +0.00% | +2.39% | +0.00% | +6.22% | +0.00% |
| Book Value per Share Growth | +5.01% | -1.21% | +3.11% | +2.71% | +0.00% |
| Debt Growth | +0.00% | +3.11% | +0.00% | +1.35% | +0.00% |
| R&D Expense Growth | +0.00% | -3.52% | +0.00% | +0.00% | +0.00% |
| SG&A Expenses Growth | +0.00% | +19.09% | -100.00% | +4.95% | +0.00% |